0000950170-24-041237.txt : 20240403
0000950170-24-041237.hdr.sgml : 20240403
20240403170005
ACCESSION NUMBER: 0000950170-24-041237
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240401
FILED AS OF DATE: 20240403
DATE AS OF CHANGE: 20240403
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nickerson Joan
CENTRAL INDEX KEY: 0001964461
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40489
FILM NUMBER: 24819796
MAIL ADDRESS:
STREET 1: C/O VERVE THERAPEUTICS, INC.
STREET 2: 201 BROOKLINE AVENUE, SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Verve Therapeutics, Inc.
CENTRAL INDEX KEY: 0001840574
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 824800132
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
BUSINESS PHONE: (978) 501-3026
MAIL ADDRESS:
STREET 1: 201 BROOKLINE AVENUE
STREET 2: SUITE 601
CITY: BOSTON
STATE: MA
ZIP: 02215
4
1
ownership.xml
4
X0508
4
2024-04-01
0001840574
Verve Therapeutics, Inc.
VERV
0001964461
Nickerson Joan
C/O VERVE THERAPEUTICS, INC.
201 BROOKLINE AVENUE, SUITE 601
BOSTON
MA
02215
false
true
false
false
Chief Administrative Officer
true
Common Stock
2024-04-01
4
M
false
3315
A
10173
D
Common Stock
2024-04-02
4
S
false
1514
8.24
D
8659
D
Restricted Stock Units
2024-04-01
4
M
false
3315
0
D
Common Stock
3315
9945
D
Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
Includes 1,364 shares of the Company's common stock acquired in 2023 under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 17, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
On February 14, 2023, the reporting person was granted 13,260 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2024 and the remainder vesting in equal annual installments until April 1, 2027.
/s/ Andrew Ashe, as Attorney-in-Fact for Joan Nickerson
2024-04-03